These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 18422469)

  • 1. Pharmacogenetics: potential role in the treatment of diabetes and obesity.
    Vella A; Camilleri M
    Expert Opin Pharmacother; 2008 May; 9(7):1109-19. PubMed ID: 18422469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype-based risk and pharmacogenetic sampling in clinical trials.
    Schork NJ; Topol EJ
    J Biopharm Stat; 2010 Mar; 20(2):315-33. PubMed ID: 20309761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future.
    Ingelsson E; McCarthy MI
    Circ Genom Precis Med; 2018 Jun; 11(6):e002090. PubMed ID: 29899044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics for type 2 diabetes: practical considerations for study design.
    Vella A
    J Diabetes Sci Technol; 2009 Jul; 3(4):705-9. PubMed ID: 20144317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Need for Precision Medicine to be Applied to Diabetes.
    Klonoff DC; Florez JC; German M; Fleming A
    J Diabetes Sci Technol; 2020 Nov; 14(6):1122-1128. PubMed ID: 31903769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice?
    Lango H; Weedon MN
    J Intern Med; 2008 Jan; 263(1):16-27. PubMed ID: 18088250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
    Walford GA; Colomo N; Todd JN; Billings LK; Fernandez M; Chamarthi B; Warner AS; Davis J; Littleton KR; Hernandez AM; Fanelli RR; Lanier A; Barbato C; Ackerman RJ; Khan SQ; Bui R; Garber L; Stolerman ES; Moore AF; Huang C; Kaur V; Harden M; Taylor A; Chen L; Manning AK; Huang P; Wexler D; McCarthy RM; Lo J; Thomas MK; Grant RW; Goldfine A; Hudson MS; Florez JC
    PLoS One; 2015; 10(3):e0121553. PubMed ID: 25812009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
    Florez JC
    Diabetologia; 2017 May; 60(5):800-807. PubMed ID: 28283684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes.
    Engelbrechtsen L; Andersson E; Roepstorff S; Hansen T; Vestergaard H
    Pharmacogenet Genomics; 2015 Oct; 25(10):475-84. PubMed ID: 26181639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic mapping of pharmacogenetic regulatory variation.
    Raby BA
    Curr Pharm Des; 2009; 15(32):3773-81. PubMed ID: 19925428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the genetics of common obesity and type 2 diabetes.
    Vimaleswaran KS; Loos RJ
    Expert Rev Mol Med; 2010 Feb; 12():e7. PubMed ID: 20184785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifestyle and genetics in obesity and type 2 diabetes.
    Temelkova-Kurktschiev T; Stefanov T
    Exp Clin Endocrinol Diabetes; 2012 Jan; 120(1):1-6. PubMed ID: 21915815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the Pathogenesis, Therapeutic Targets/Drug Action and Pharmacogenetics of Type 2 Diabetes: Is there a Future for Personalised Medicine?
    Engwa GA; Nweke FN; Karngong GN; Afiukwa CA; Nwagu KE
    Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1569-1589. PubMed ID: 32334506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy.
    Moore AF; Florez JC
    Annu Rev Med; 2008; 59():95-111. PubMed ID: 17937592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
    Kyriakidou A; Koufakis T; Goulis DG; Vasilopoulos Y; Zebekakis P; Kotsa K
    Curr Pharm Des; 2021; 27(8):1025-1034. PubMed ID: 33272167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity.
    Lindgren CM; McCarthy MI
    Nat Clin Pract Endocrinol Metab; 2008 Mar; 4(3):156-63. PubMed ID: 18212765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical implications of understanding complex disease traits.
    Bell J
    Curr Opin Biotechnol; 1998 Dec; 9(6):573-7. PubMed ID: 9889146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and target identification in diabetes.
    Pearson ER
    Curr Opin Genet Dev; 2018 Jun; 50():68-73. PubMed ID: 29486427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenetics of oral antidiabetic treatment].
    Tkáč I
    Vnitr Lek; 2016 Mar; 62(3):186-8. PubMed ID: 27180666
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.